JMB-HEADER RAS-JOURNALS EIMB Pleiades Publishing

RUS

             

ENG

YearIMPACT-FACTOR
2022  1,200
2021  1,540
2020  1,374
2019  1,023
2018  0,932
2017  0,977
2016  0,799
2015  0,662
2014  0,740
2013  0,739
2012  0,637
2011  0,658
2010  0,654
2009  0,570
2008  0,849
2007  0,805
2006  0,330
2005  0,435
2004  0,623
2003  0,567
2002  0,641
2001  0,490
2000  0,477
1999  0,762
1998  0,785
1997  0,507
1996  0,518
1995  0,502
Vol 55(2021) N 6 p. 941-949; DOI 10.1134/S0026893321050137 Full Text

H.N.N. Thu1, H.T.N. Vy1, T.N.N. Thanh2, D.T.N. Giang1, T.N. Nhan1, N.P. Hoang1, T.N. Hue2*

miRNA-16 AS an Internal Control in Breast Cancer Studies: A Systematic Review and Meta-analysis

1Vietnam National University, Ho Chi Minh City, 70000 Vietnam
2Department of Physiology and Animal Biotechnology, Faculty of Biology and Biotechnology, University of Science, Ho Chi Minh City, 70000 Vietnam

*nthue@hcmus.edu.vn
Received - 2020-12-12; Revised - 2021-02-10; Accepted - 2021-02-24

Reverse Transcription quantitative Polymerase Chain Reaction (RT-qPCR) is a method of choice for quantifying micro RNAs (miRNAs). Typically, RT-qPCR data are normalized to reference genes. While miRNAs are used for diagnosing and subtyping breast cancer, various studies show their deregulation in this condition, thus, undermining miRNAs' utility as a reference. This review examines the expression pattern of miR-16 and suggests normalization approaches for breast cancer. We analyzed the data from selected peer-reviewed studies to calculate the standardized mean difference (SMD) with subsequent Chi-square testing and identified the difference in miR-16 expression between breast cancer patients and healthy controls. With a negative SMD value of-0.56 and Chi-square of 62.62 (p-value = 0.05), the deregulation of miR-16 in breast cancer was confirmed. High variance in the stability value (SV) of miR-16 expression levels confirmed its inappropriateness as a control gene in breast cancer. The combination of miR-16 and miR-425 was confirmed as an accurate endogenous control.

breast cancer, miR-16, internal control, combined control genes



JMB-FOOTER RAS-JOURNALS